Related Experiment Videos
[Clinical evaluation of cefminox in children]
Insights
Cefminox (CMNX), a new cephem antibiotic, showed high blood levels and rapid excretion in children. It proved effective and safe for treating pediatric infections.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antibiotic Therapy
Background:
- Pediatric infections require effective and safe antimicrobial agents.
- The cephem group of antibiotics offers a broad spectrum of activity.
- New antibiotic development is crucial for combating resistant pathogens.
Purpose of the Study:
- To evaluate the pharmacokinetic profile, clinical efficacy, and safety of cefminox (CMNX) in pediatric patients.
- To determine the absorption, excretion, and half-life of CMNX following intravenous administration.
- To assess the clinical effectiveness and tolerability of CMNX in children with various infections.
Main Methods:
- A total of 13 pediatric patients (1 month to 6 years) with infections received cefminox (CMNX) via intravenous drip infusion.
- Pharmacokinetic parameters including blood levels and half-life were determined.
- Clinical outcomes and laboratory findings were monitored to assess efficacy and safety.
Main Results:
- Cefminox (CMNX) achieved high blood concentrations with a half-life of approximately 1 hour.
- Urinary recovery of CMNX was around 80% within 6 hours post-administration.
- Clinical efficacy was observed in 66.7% (8/12) of assessable cases, with no reported side effects or abnormal laboratory findings.
Conclusions:
- Cefminox (CMNX) demonstrates favorable pharmacokinetic properties and a good safety profile in pediatric patients.
- The antibiotic is considered effective for treating infections in children.
- Cefminox (CMNX) is a promising new therapeutic option for pediatric infectious diseases.
Abstract:
In a total of 13 children with infections, ranging in age from 1 month to 6 years, cefminox (CMNX, MT-141), a new antibiotic of cephem group, was administered 14 times and its absorption, excretion, clinical results and safety were determined. Following intravenous drip infusion of CMNX, high blood level was achieved, with half-life of about 1 hour (0.77 to 1.13 hours). The urinary recovery rate was approximately 80% within the first 6 hours after completion of administration. Clinical results were rated as effective in 8 out of 12 assessable cases (66.7%). In any of the cases treated no side effects developed nor any abnormal changes in laboratory finding were observed. From these results, CMNX is considered to be a new antibiotic useful and safe for use in the field of pediatrics.